NCT04224064Recruiting
Identification of a New Blood Biomarker for the Diagnosis and Prognosis of Liposarcomas
Source: ClinicalTrials.gov · Last updated 12 Feb 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main objective of this project is to identify a new non-invasive biological test for the diagnosis of LPS by measuring circulating serine levels. The current gold standard is the detection of Mdm2 amplification by the FISH.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 158 (estimated)
- First submitted
- 8 Jan 2020
- Start date
- 26 Aug 2020
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
- Diseases
- Sarcoma
- NCT number
- NCT04224064
What you commit to
- Study type: Interventional
- Planned participants: 158
- From 26 Aug 2020 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of NeoAdjuvant Treatment for the present cancer, Unaffiliated patient to French Social Protection System, Patient whose follow up is impossible for psychologic, social, geographic, familial reasons Psychiatric illness that would prevent the patient from giving informed consent or being compliant with the study procedures Patient who have another cancer within the 5 years of the inclusion except in situ breast carcinoma, in situ, basocellular carcinoma.
Other
- Pregnancy and/or feeding
Who the study is looking for
- Men/women older than 18 years old,
- Surgery for :
- Localized WD-LPS and DD-LPS, and/or
- WD-LPS or DD-LPS local relapse, and/or
- WD-LPS or DD-LPS distant relapse and/or
- Deep adipocytic tumor greater than 5 cms, suggestive of atypical lipomatous tumor Patient accepting blood sample, Patient who signed informed consent
- Men/women older than 18 years old, Accepting blood sample, Who signed informed consent Matching on sex and age on LPS patient cohort
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institut du Cancer de Montpellier - Val d'Aurelle Coordinator of this site? Confirm its status | Montpellier | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.